Citation: | Xiao-Wen Zhang, Xiang-Xing Zhu, Dong-Sheng Tang, Jia-Hong Lu. Targeting autophagy in Alzheimer’s disease: Animal models and mechanisms. Zoological Research, 2023, 44(6): 1132-1145. doi: 10.24272/j.issn.2095-8137.2023.294 |
[1] |
Abd-Elrahman KS, Hamilton A, Vasefi M, et al. 2018. Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer’s disease mouse models.
|
[2] |
Armstrong RA. 2019. Risk factors for Alzheimer’s disease.
|
[3] |
Arnsten AFT, Datta D, Del Tredici K, et al. 2021. Hypothesis: tau pathology is an initiating factor in sporadic Alzheimer's disease. Alzheimer's & Dementia, 17(1): 115−124.
|
[4] |
Beckman D, Chakrabarty P, Ott S, et al. 2021. A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. Alzheimer’s & Dementia, 17(6): 933−945.
|
[5] |
Bondolfi L, Calhoun M, Ermini F, et al. 2002. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice.
|
[6] |
Bourdenx M, Martín-Segura A, Scrivo A, et al. 2021. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome.
|
[7] |
Caballero B, Bourdenx M, Luengo E, et al. 2021. Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice.
|
[8] |
Cai CZ, Zhuang XX, Zhu Q, et al. 2022. Enhancing autophagy maturation with CCZ1-MON1A complex alleviates neuropathology and memory defects in Alzheimer disease models.
|
[9] |
Cai ZY, Yan LJ. 2013. Rapamycin, autophagy, and Alzheimer’s disease. Journal of Biochemical and Pharmacological Research, 1(2): 84−90.
|
[10] |
Cavieres VA, González A, Muñoz VC, et al. 2015. Tetrahydrohyperforin inhibits the proteolytic processing of amyloid precursor protein and enhances its degradation by Atg5-dependent autophagy.
|
[11] |
Cen XF, Chen YY, Xu XY, et al. 2020. Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an Alzheimer’s disease mouse model.
|
[12] |
Chang J, Li YJ, Shan XQ, et al. 2024. Neural stem cells promote neuroplasticity: a promising therapeutic strategy for the treatment of Alzheimer's disease.
|
[13] |
Chen CY, Yang C, Wang J, et al. 2021a. Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease.
|
[14] |
Chen Gf, Xu Th, Yan Y, et al. 2017. Amyloid beta: structure, biology and structure-based therapeutic development.
|
[15] |
Chen ML, Hong CG, Yue T, et al. 2021b. Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy.
|
[16] |
Chen ZY, Zhang Y. 2022. Animal models of Alzheimer’s disease: applications, evaluation, and perspectives.
|
[17] |
Chesser AS, Ganeshan V, Yang J, et al. 2016. Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons.
|
[18] |
Colacurcio DJ, Nixon RA. 2016. Disorders of lysosomal acidification—The emerging role of v-ATPase in aging and neurodegenerative disease.
|
[19] |
Cummins N, Tweedie A, Zuryn S, et al. 2019. Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria.
|
[20] |
Cuyvers E, Sleegers K. 2016. Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond.
|
[21] |
de la Cueva M, Antequera D, Ordoñez-Gutierrez L, et al. 2022. Amyloid-β impairs mitochondrial dynamics and autophagy in Alzheimer’s disease experimental models.
|
[22] |
De Strooper B. 2003. Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex.
|
[23] |
Deng ZQ, Dong Y, Zhou XT, et al. 2022. Pharmacological modulation of autophagy for Alzheimer's disease therapy: opportunities and obstacles.
|
[24] |
Di Meco A, Curtis ME, Lauretti E, et al. 2020. Autophagy dysfunction in Alzheimer’s disease: mechanistic insights and new therapeutic opportunities.
|
[25] |
Drummond E, Wisniewski T. 2017. Alzheimer’s disease: experimental models and reality.
|
[26] |
Edbauer D, Winkler E, Regula JT, et al. 2003. Reconstitution of γ-secretase activity.
|
[27] |
Esquerda-Canals G, Montoliu-Gaya L, Güell-Bosch J, et al. 2017. Mouse models of Alzheimer’s disease.
|
[28] |
Falangola MF, Nie XJ, Ward R, et al. 2020. Diffusion MRI detects early brain microstructure abnormalities in 2-month-old 3×Tg-AD mice.
|
[29] |
Fang EF, Hou YJ, Palikaras K, et al. 2019. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease.
|
[30] |
Fedeli C, Filadi R, Rossi A, et al. 2019. PSEN2 (presenilin 2) mutants linked to familial Alzheimer disease impair autophagy by altering Ca2+ homeostasis.
|
[31] |
Feng Q, Luo Y, Zhang XN, et al. 2020. MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration.
|
[32] |
Feng YM, Jia YF, Su LY, et al. 2013. Decreased mitochondrial DNA copy number in the hippocampus and peripheral blood during opiate addiction is mediated by autophagy and can be salvaged by melatonin.
|
[33] |
Fleming A, Bourdenx M, Fujimaki M, et al. 2022. The different autophagy degradation pathways and neurodegeneration.
|
[34] |
Freitag K, Sterczyk N, Wendlinger S, et al. 2022. Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer’s disease mouse model.
|
[35] |
Frisoni GB, Altomare D, Thal DR, et al. 2022. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.
|
[36] |
Frost B, Jacks RL, Diamond MI. 2009. Propagation of tau misfolding from the outside to the inside of a cell.
|
[37] |
Goodarzi P, Payab M, Alavi-Moghadam S, et al. 2019. Development and validation of Alzheimer’s disease animal model for the purpose of regenerative medicine.
|
[38] |
Graff-Radford J, Yong KXX, Apostolova LG, et al. 2021. New insights into atypical Alzheimer's disease in the era of biomarkers.
|
[39] |
Hamano T, Enomoto S, Shirafuji N, et al. 2021. Autophagy and tau protein.
|
[40] |
Hao FJ, Feng YQ. 2021. Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimer's mice uncovered by RNA-seq.
|
[41] |
Hardy J, Allsop D. 1991. Amyloid deposition as the central event in the aetiology of Alzheimer's disease.
|
[42] |
Heckmann BL, Teubner BJW, Boada-Romero E, et al. 2020. Noncanonical function of an autophagy protein prevents spontaneous Alzheimer’s disease.
|
[43] |
Hinz FI, Geschwind DH. 2017. Molecular genetics of neurodegenerative dementias.
|
[44] |
Honjo K, Black SE, Verhoeff NPLG. 2012. Alzheimer's disease, cerebrovascular disease, and the β-amyloid cascade.
|
[45] |
Jay TR, Miller CM, Cheng PJ, et al. 2015. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models.
|
[46] |
Jucker M, Walker LC. 2023. Alzheimer's disease: from immunotherapy to immunoprevention.
|
[47] |
Kanemoto S, Griffin J, Markham-Coultes K, et al. 2014. Proliferation, differentiation and amyloid-β production in neural progenitor cells isolated from TgCRND8 mice.
|
[48] |
Kim TA, Syty MD, Wu K, et al. 2022. Adult hippocampal neurogenesis and its impairment in Alzheimer’s disease.
|
[49] |
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. 2021. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).
|
[50] |
Knight R, Khondoker M, Magill N, et al. 2018. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia.
|
[51] |
Kou XJ, Chen DD, Chen N. 2020. The regulation of microRNAs in Alzheimer's disease.
|
[52] |
Kou XJ, Chen N. 2017. Resveratrol as a natural autophagy regulator for prevention and treatment of Alzheimer’s disease.
|
[53] |
Lachance V, Wang Q, Sweet E, et al. 2019. Autophagy protein NRBF2 has reduced expression in Alzheimer’s brains and modulates memory and amyloid-beta homeostasis in mice.
|
[54] |
Lanoiselée HM, Nicolas G, Wallon D, et al. 2017. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases.
|
[55] |
Lee JH, Yang DS, Goulbourne CN, et al. 2022. Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques.
|
[56] |
Lee JH, Yu WH, Kumar A, et al. 2010. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations.
|
[57] |
Lee YS, Lai DM, Huang HJ, et al. 2021. Prebiotic lactulose ameliorates the cognitive deficit in Alzheimer’s disease mouse model through macroautophagy and chaperone-mediated autophagy pathways.
|
[58] |
Levine B, Kroemer G. 2019. Biological functions of autophagy genes: a disease perspective.
|
[59] |
Leyton E, Matus D, Espinoza S, et al. 2021. DEF8 and autophagy-associated genes are altered in mild cognitive impairment, probable Alzheimer’s disease patients, and a transgenic model of the disease.
|
[60] |
Li H, Zheng TT, Lian FZ, et al. 2022. Anthocyanin-rich blueberry extracts and anthocyanin metabolite protocatechuic acid promote autophagy-lysosomal pathway and alleviate neurons damage in in vivo and in vitro models of Alzheimer's disease.
|
[61] |
Li HL, Xiang BL, Li X, et al. 2023. Cognitive deficits and Alzheimer's disease-like pathologies in the aged Chinese tree shrew. Molecular Neurobiology, doi: https://doi.org/10.1007/s12035-023-03663-7.
|
[62] |
Li LX, Zhang SF, Zhang X, et al. 2013. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease.
|
[63] |
Li Q, Liu Y, Sun M. 2017. Autophagy and Alzheimer’s disease.
|
[64] |
Li Y, Xu M, Ding X, et al. 2016. Protein kinase C controls lysosome biogenesis independently of mTORC1.
|
[65] |
Liao F, Zhang TJ, Jiang H, et al. 2015. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.
|
[66] |
Lilja AM, Röjdner J, Mustafiz T, et al. 2013. Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels.
|
[67] |
Litwiniuk A, Juszczak GR, Stankiewicz AM, et al. 2023. The role of glial autophagy in Alzheimer’s disease. Molecular Psychiatry, doi: https://doi.org/10.1038/s41380-023-02242-5.
|
[68] |
Liu CC, Kanekiyo T, Xu HX, et al. 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.
|
[69] |
Liu XL, Huang SH, Wang XQ, et al. 2015. Chaperone-mediated autophagy and neurodegeneration: connections, mechanisms, and therapeutic implications.
|
[70] |
Lok K, Zhao H, Shen HL, et al. 2013. Characterization of the APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background.
|
[71] |
Long JM, Holtzman DM. 2019. Alzheimer disease: an update on pathobiology and treatment strategies.
|
[72] |
Lu BW, Vogel H. 2009. Drosophila models of neurodegenerative diseases.
|
[73] |
Luo RC, Su LY, Li GY, et al. 2020. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.
|
[74] |
Lynch C. 2020. World Alzheimer Report 2019: attitudes to dementia, a global survey: public health: engaging people in ADRD research. Alzheimer's & Dementia, 16(S10): e038255.
|
[75] |
Martini-Stoica H, Xu Y, Ballabio A, et al. 2016. The autophagy-Lysosomal pathway in neurodegeneration: a TFEB perspective.
|
[76] |
Matsunaga S, Kishi T, Annas P, et al. 2015. Lithium as a treatment for Alzheimer’s disease: a systematic review and meta-analysis.
|
[77] |
Miceli C, Leri M, Stefani M, et al. 2023. Autophagy-related proteins: potential diagnostic and prognostic biomarkers of aging-related diseases.
|
[78] |
Moreau K, Fleming A, Imarisio S, et al. 2014. PICALM modulates autophagy activity and tau accumulation.
|
[79] |
Mueller-Steiner S, Zhou YG, Arai H, et al. 2006. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease.
|
[80] |
Nakai T, Yamada K, Mizoguchi H. 2021. Alzheimer’s disease animal models: elucidation of biomarkers and therapeutic approaches for cognitive impairment.
|
[81] |
Nediani C, Ruzzolini J, Romani A, et al. 2019. Oleuropein, a bioactive compound from Olea europaea L., as a potential preventive and therapeutic agent in non-communicable diseases.
|
[82] |
Nilsson P, Sekiguchi M, Akagi T, et al. 2015. Autophagy-related protein 7 deficiency in amyloid β (Aβ) precursor protein transgenic mice decreases Aβ in the multivesicular bodies and induces Aβ accumulation in the Golgi.
|
[83] |
Oakley H, Cole SL, Logan S, et al. 2006. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation.
|
[84] |
O’Keefe L, Denton D. 2018. Using Drosophila models of amyloid toxicity to study autophagy in the pathogenesis of Alzheimer’s disease. BioMed Research International, 2018: 5195416.
|
[85] |
Piras A, Collin L, Grüninger F, et al. 2016. Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy.
|
[86] |
Pomilio C, Gorojod RM, Riudavets M, et al. 2020. Microglial autophagy is impaired by prolonged exposure to β-amyloid peptides: evidence from experimental models and Alzheimer’s disease patients.
|
[87] |
Pupyshev AB, Belichenko VM, Tenditnik MV, et al. 2022. Combined induction of mTOR-dependent and mTOR-independent pathways of autophagy activation as an experimental therapy for Alzheimer's disease-like pathology in a mouse model.
|
[88] |
Qin C, Li YN, Wang KW. 2021a. Functional mechanism of bone marrow-derived mesenchymal stem cells in the treatment of animal models with Alzheimer’s disease: inhibition of neuroinflammation.
|
[89] |
Qin C, Li YN, Wang KW. 2021b. Novel balance mechanism participates in stem cell therapy to alleviate neuropathology and cognitive impairment in animal models with Alzheimer’s disease.
|
[90] |
Qiu WQ, Pan R, Tang Y, et al. 2020. Lychee seed polyphenol inhibits Aβ-induced activation of NLRP3 inflammasome via the LRP1/AMPK mediated autophagy induction. Biomedicine & Pharmacotherapy, 130: 110575.
|
[91] |
Querfurth HW, LaFerla FM. 2010. Alzheimer's disease.
|
[92] |
Raha S, Ghosh A, Dutta D, et al. 2021. Activation of PPARα enhances astroglial uptake and degradation of β-amyloid.
|
[93] |
Reddy PH, Yin XL, Manczak M, et al. 2018. Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer’s disease.
|
[94] |
Rhein V, Song XM, Wiesner A, et al. 2009. Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proceedings of the National Academy of Sciences of the United States of America, 106(47): 20057−20062.
|
[95] |
Rocchi A, Yamamoto S, Ting T, et al. 2017. A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease.
|
[96] |
Roltsch E, Holcomb L, Young KA, et al. 2010. PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition in response to S100B ablation.
|
[97] |
Salehi B, Stojanović-Radić Z, Matejić J, et al. 2019. The therapeutic potential of curcumin: a review of clinical trials.
|
[98] |
Salem MA, Budzyńska B, Kowalczyk J, et al. 2021. Tadalafil and bergapten mitigate streptozotocin-induced sporadic Alzheimer's disease in mice via modulating neuroinflammation, PI3K/Akt, Wnt/β-catenin, AMPK/mTOR signaling pathways.
|
[99] |
Salminen A, Kaarniranta K, Kauppinen A, et al. 2013. Impaired autophagy and APP processing in Alzheimer's disease: the potential role of Beclin 1 interactome. Progress in Neurobiology, 106–107: 33–54.
|
[100] |
Serrano-Pozo A, Das S, Hyman BT. 2021. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
|
[101] |
Sexton C, Snyder H, Beher D, et al. 2022. Current directions in tau research: highlights from Tau 2020. Alzheimer's & Dementia, 18(5): 988−1007.
|
[102] |
Shi Y, Yamada K, Liddelow SA, et al. 2017. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.
|
[103] |
Sonawane SK, Chinnathambi S. 2018. Prion-like propagation of post-translationally modified tau in Alzheimer’s disease: a hypothesis.
|
[104] |
Sorrentino V, Romani M, Mouchiroud L, et al. 2017. Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity.
|
[105] |
Sose PM, Doshi GM, Kale PP. 2023. An update on autophagy as a target in the treatment of Alzheimer's disease.
|
[106] |
Spilman P, Podlutskaya N, Hart MJ, et al. 2010. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease.
|
[107] |
Su LY, Li H, Lv L, et al. 2015. Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation.
|
[108] |
Su LY, Luo RC, Liu QJ, et al. 2017. Atg5- and Atg7-dependent autophagy in dopaminergic neurons regulates cellular and behavioral responses to morphine.
|
[109] |
Subramanian M, Hyeon SJ, Das T, et al. 2021. UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation.
|
[110] |
Tavares IA, Touma D, Lynham S, et al. 2013. Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease.
|
[111] |
Temple S. 2023. Advancing cell therapy for neurodegenerative diseases.
|
[112] |
Thakral S, Yadav A, Singh V, et al. 2023. Alzheimer's disease: molecular aspects and treatment opportunities using herbal drugs.
|
[113] |
Tong BCK, Wu AJ, Huang AS, et al. 2022. Lysosomal TPCN (two pore segment channel) inhibition ameliorates beta-amyloid pathology and mitigates memory impairment in Alzheimer disease.
|
[114] |
Trumbore CN. 2016. Shear-induced amyloid formation in the brain: I. Potential vascular and parenchymal processes.
|
[115] |
Venkatramani A, Panda D. 2019. Regulation of neuronal microtubule dynamics by tau: implications for tauopathies.
|
[116] |
Wang NB, Wang HY, Pan Q, et al. 2021. The combination of β-asarone and icariin inhibits amyloid-β and reverses cognitive deficits by promoting mitophagy in models of Alzheimer’s disease. Oxidative Medicine and Cellular Longevity, 2021: 7158444.
|
[117] |
Wang SL, Long HJ, Hou LJ, et al. 2023. The mitophagy pathway and its implications in human diseases.
|
[118] |
Wang W, Gu XH, Cheng ZJ, et al. 2022. IKKβ alleviates neuron injury in Alzheimer’s disease via regulating autophagy and RIPK1-mediated necroptosis.
|
[119] |
Wang XC, Jia JP. 2023. Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway. Biomedicine & Pharmacotherapy, 161: 114473.
|
[120] |
Wang YP, Martinez-Vicente M, Krüger U, et al. 2009. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing.
|
[121] |
Wang YT, Lu JH. 2022. Chaperone-mediated autophagy in neurodegenerative diseases: molecular mechanisms and pharmacological opportunities.
|
[122] |
Webster SJ, Bachstetter AD, Nelson PT, et al. 2014. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Frontiers in Genetics, 5: 88.
|
[123] |
Wu SS, Wei YF, Li JX, et al. 2021. SIRT5 represses neurotrophic pathways and Aβ production in Alzheimer’s disease by targeting autophagy.
|
[124] |
Xie CL, Zhuang XX, Niu ZM, et al. 2022. Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow.
|
[125] |
Xie ZS, Zhao JP, Wu LM, et al. 2023. Hederagenin improves Alzheimer's disease through PPARα/TFEB-mediated autophagy.
|
[126] |
Xu C, Wu JL, Wu YQ, et al. 2021a. TNF-α-dependent neuronal necroptosis regulated in Alzheimer's disease by coordination of RIPK1-p62 complex with autophagic UVRAG.
|
[127] |
Xu XY, Sun YQ, Cen XF, et al. 2021b. Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model. Protein & Cell, 12(10): 769−787.
|
[128] |
Xu Y, Du SQ, Marsh JA, et al. 2021c. TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading.
|
[129] |
Yang Y, Wang JZ. 2018. Nature of tau-associated neurodegeneration and the molecular mechanisms.
|
[130] |
Yang Y, Zhang LH. 2020. The effects of caloric restriction and its mimetics in Alzheimer's disease through autophagy pathways. Food & Function, 11(2): 1211−1224.
|
[131] |
Yelleswarapu NK, Masino M, Henderson S, et al. 2022. 5xFAD mice do not have myenteric amyloidosis, dysregulation of neuromuscular transmission or gastrointestinal dysmotility. Neurogastroenterology & Motility, 34(12): e14439.
|
[132] |
Yin LM, Zhou JH, Li TY, et al. 2023. Inhibition of the dopamine transporter promotes lysosome biogenesis and ameliorates Alzheimer's disease–like symptoms in mice. Alzheimer's & Dementia, 19(4): 1343−1357.
|
[133] |
Yuan P, Zhang MY, Tong L, et al. 2022. PLD3 affects axonal spheroids and network defects in Alzheimer’s disease.
|
[134] |
Zare-Shahabadi A, Masliah E, Johnson GVW, et al. 2015. Autophagy in Alzheimer’s disease. Reviews in the Neurosciences, 26(4): 385−395.
|
[135] |
Zeng K, Yu X, Mahaman YAR, et al. 2022. Defective mitophagy and the etiopathogenesis of Alzheimer's disease.
|
[136] |
Zeng Q, Siu W, Li LM, et al. 2019. Autophagy in Alzheimer's disease and promising modulatory effects of herbal medicine.
|
[137] |
Zhang DF, Xu M, Bi R, et al. 2019. Genetic analyses of Alzheimer's disease in China: achievements and perspectives.
|
[138] |
Zhang H, Knight C, Chen SRW, et al. 2023. A gating mutation in ryanodine receptor type 2 rescues phenotypes of Alzheimer’s disease mouse models by upregulating neuronal autophagy.
|
[139] |
Zhang H, Liang JL, Chen N. 2022a. The potential role of miRNA-regulated autophagy in Alzheimer's disease.
|
[140] |
Zhang JY, Ma S, Liu XL, et al. 2022b. Activating transcription factor 6 regulates cystathionine to increase autophagy and restore memory in Alzheimer’s disease model mice.
|
[141] |
Zhang ST, Wang Z, Cai F, et al. 2017a. BACE1 cleavage site selection critical for amyloidogenesis and Alzheimer's pathogenesis.
|
[142] |
Zhang W, Yang YW, Xiang ZF, et al. 2022c. MRTF-A-mediated protection against amyloid-β-induced neuronal injury correlates with restoring autophagy via miR-1273g-3p/mTOR axis in Alzheimer models.
|
[143] |
Zhang WW, Feng C, Jiang H. 2021a. Novel target for treating Alzheimer's Diseases: crosstalk between the Nrf2 pathway and autophagy.
|
[144] |
Zhang XD, Liang X, Gu JJ, et al. 2017b. Investigation and intervention of autophagy to guide cancer treatment with nanogels.
|
[145] |
Zhang ZG, Yang XF, Song YQ, et al. 2021b. Autophagy in Alzheimer’s disease pathogenesis: therapeutic potential and future perspectives.
|
[146] |
Zhou SL, Tan CC, Hou XH, et al. 2019. TREM2 variants and neurodegenerative diseases: a systematic review and meta-analysis.
|
[147] |
Zhu ZK, Liu YX, Li XY, et al. 2022. GPNMB mitigates Alzheimer’s disease and enhances autophagy via suppressing the mTOR signal.
|